Arcturus医疗 ARCT 深 沪
等待开盘 06-26 09:30:00 美东时间
6.815
-0.195
-2.78%
华盛通- 最 高7.87
- 今 开7.01
- 成交量 28.81万股
- 最 低 6.80
- 昨 收 7.01
- 总市值 18.00万
- 52周最高 24.14
- 市盈率 静 --
- 换手率 1090.66%
- 52周最低 5.85
- 委 比 37.17%
- 总股本 2.64万
- 历史最高 129.71
- 量 比 0.74
- 振 幅 15.26%
- 历史最低 1.10
- 每 手 1
- 风险率 4.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews
In the preceding three months, 4 analysts have released ratings for Arcturus Th...
03-06 06:01
Arcturus Therapeutics Q4 Earnings Assessment
Arcturus Therapeutics (NASDAQ:ARCT) announced its Q4 earnings on Tuesday, March...
03-04 05:02
Earnings Preview: Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT) is gearing up to announce its quarterly ear...
03-03 01:02
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Preview: Arcturus Therapeutics's Earnings
Arcturus Therapeutics (NASDAQ:ARCT) is gearing up to announce its quarterly ear...
2025-11-08 02:05
为了让始祖鸟当网红，安踏把灵魂丢了
来源：源媒汇 作者 | 王言 在被全网捧成“网红”后，始祖鸟还是迎来了营销的反噬。 9月19日，艺术家蔡国强与户外品牌始祖鸟联手，在西藏喜马拉雅山脉江孜...
2025-09-22 17:27
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics has initiated a Phase 2 study to evaluate ZORYVE 0.05% cream in infants 3 months to under 2 years with atopic dermatitis. The four-week study will assess safety and tolerability of once-daily use, addressing limited treatment options for this age group. Atopic dermatitis affects 9.6 million children in the U.S., with up to 60% developing symptoms within the first year.
2025-06-10 12:00
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted 72,000 restricted stock units to 9 new employees under its 2022 Inducement Plan, with a grant date of June 2, 2025. The units vest over four years.
2025-06-06 20:00
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
New data from the INTEGUMENT-OLE study show that ZORYVE cream provides long-term improvement in atopic dermatitis symptoms, with children aged 2–5 achieving disease control for up to 238 days. The cream also demonstrated consistent safety and tolerability.
2025-06-06 12:00
